We then developed a PD-1 expressing Jurkat NFAT reporter cell line to measure TCR signaling and found that EVs shed from glioma cells are capable of inhibiting TCR signaling in a dose-dependent and PD-L1-specific manner. This evidence concerns the gene CD274 and central nervous system cancer.